Skip to main content

Table 2 The liver function tests in serum of control and NAFLD groups

From: The role of hepatic transcription factor cAMP response element-binding protein (CREB) during the development of experimental nonalcoholic fatty liver: a biochemical and histomorphometric study

Weeks

ALT

AST

GGT

Total bilirubin

Direct bilirubin

 

Control

NAFLD

Control

NAFLD

Control

NAFLD

Control

NAFLD

Control

NAFLD

2

10.6 ± 1.29

18.6 ± 0.51*

12.2 ± 1.02

21.6 ± 1.21*

9.2 ± 0.73

16.8 ± 1.16*

0.59 ± 0.05

1.41 ±0.05*

0.04 ± 0.02

0.18 ± 0.02*

4

12.0 ± 1.05

21.0 ± 1.38*#

13.8 ± 1.59

24.4 ± 1.54*#

10.4 ± 0.75

24.1 ± 2.32*#

0.58 ± 0.05

2.03 ± 0.06*#

0.07 ± 0.02

0.21 ± 0.01*

6

15.4 ± 1.57

28.6 ± 1.69*#

17.8 ± 1.39

39.4 ± 2.25*#

10.6 ± 1.40

34.4 ± 2.38*#

0.65 ± 0.06

2.65 ± 0.12*#

0.05 ± 0.02

0.22 ± 0.02*

8

13.6 ± 0.75

35.8 ± 1.93*#

17.0 ± 1.00

46.1 ± 1.79*#

11.8 ± 0.66

41.0 ± 1.95*#

0.67 ± 0.04

3.12 ± 0.23*#

0.07 ± 0.01

0.29 ± 0.02*

10

13.4 ± 1.03

40.8 ± 2.31*#

17.0 ± 1.76

53.8 ± 2.84*#

11.2 ± 0.84

46.0 ± 3.86*#

0.69 ± 0.05

3.60 ± 0.16*#

0.07 ± 0.02

0.34 ± 0.02*

12

15.6 ± 0.60

49.6 ± 2.11*#

16.8 ± 1.83

64.4 ± 3.30*#

12.2 ± 2.01

53.0 ± 4.37*#

0.71 ± 0.05

3.93 ± 0.05*#

0.10 ± 0.01

0.39 ± 0.02*

14

14.8 ± 1.62

60.6 ± 3.60*#

17.8 ± 1.5

85.4 ± 2.29*#

12.4 ± 0.51

62.6 ± 3.83*#

0.70 ± 0.02

4.28 ± 0.14*#

0.13 ± 0.01

0.44 ± 0.02*

  1. Data expressed as mean ± SE
  2. *Significant difference compared to control group at the same duration period by t test (P < 0.05)
  3. #Significant difference compared to the previous duration in the same group by paired t test (P < 0.05)